Posterizan, rectal 10 pcs

Pharmacotherapeutic group: hemorrhoids treatment

ATC code: A07FA

Pharmacodynamics:

Antigens of cell walls and products of metabolism of Escherichia coli in contact with the mucosa of the rectum and the skin of the anogenital area increase local tissue resistance to pathogenic microflora.

The drug stimulates the T-lymphocytic system of cellular immunity Increases phagocytic activity of leukocytes and cells of the reticuloendothelial system Non-specific immune factors reduce vascular exudation during inflammation Normalizes the permeability and tone of blood vessels Stimulates regeneration of damaged tissues.

Indications

Posterisan® rectal suppositories are prescribed for adults (from 18 years of age) for the following diseases: anal itching and burning in the anal area due to hemorrhoids.

Composition

1 suppository contains:

The active ingredient: a standardized suspension of E. coli bacterial culture (ECB) 387.10 mg (6.6 x 108 (4.95 x 108 – 8.25 x 108) E. microcl. coli inactivated and preserved in 6.6 mg liquefied phenol);

auxiliary substances: liquefied phenol 6.60 mg (in the SCV) (corresponding to 6.0 mg solid phenol content), solid fat 1603.22 mg, macrogol glycerol hydroxystearate 9.68 mg.

How to take, the dosage

Inject one suppository into the anus in the morning and evening, if possible after defecation.

The recommended daily dose is 2 suppositories.

The combined use of Posterisan® suppositories rectal and Posterisan® ointment for rectal and external use is possible.

The course of treatment is 2-3 weeks.

Interaction

Drug interactions of the drug Posterisan have not been described.

Special Instructions

Effect on the ability to drive vehicles and machines:

Posterizan® has no effect on the ability to drive vehicles and perform work requiring increased speed of psychomotor reactions.

Contraindications

Hypersensitivity to phenol.

Side effects

Posterisan® has no side effects even with long-term use.

Phenol is used as a preservative in the drug, so allergic reactions are possible in patients with hypersensitivity to this component, in the development of which the drug should be discontinued.

Overdose

An overdose of Posterisan has not been reported at this time.